



8 February 2021

**OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")**

Statement re. media comment

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the article published online yesterday by the Financial Times.

The Company can confirm that it is continuing to modify its Alva-based facility to upscale significantly its lateral flow test production capacity. When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations.

Contacts:

Omega Diagnostics Group PLC

Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030
www.omegadiagnostics.com

finnCap Ltd

Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303